The study assessed several biomarkers, including CDKN2A, TNFRSFOB, BBC3, CCNG1, TRIAP1, CDKN1A, MDM2, FDXR, DDB2, XPC, EDA2R, RPS27L, and BAX, comparing MDM2 mRNA expression in patients to reference levels from others with the same cancer type [315]. This evidence concerns the gene CDKN2A and cancer.